Logo

Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications

Share this

Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications

Shots:

  • AbCellera to receive upfront- milestone- and royalties based on the development and commercialization of Abs- emerge under the collaboration
  • The expanded collaboration will utilize AbCellera’s technology stack- which includes Trianni Mouse and OrthoMab protein engineering platform
  • AbCellera will generate panels of Abs against up to 8 new targets across multiple indications- selected by Gilead

  Ref: BusinessWire | Image: Gilead

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions